139 related articles for article (PubMed ID: 22812184)
1. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis involving 23,998 subjects.
Yang J; Liu H; Lu S; Gao M; Du Q; Tang SC
Oncol Res; 2011; 19(12):519-25. PubMed ID: 22812184
[TBL] [Abstract][Full Text] [Related]
2. AA genotype of cyclin D1 G870A polymorphism increases breast cancer risk: Findings of a case-control study and meta-analysis.
Akhter N; Alzahrani FA; Dar SA; Wahid M; Sattar RSA; Hussain S; Haque S; Ansari SA; Jawed A; Mandal RK; Almalki S; Alharbi RA; Husain SA
J Cell Biochem; 2019 Oct; 120(10):16452-16466. PubMed ID: 31243808
[TBL] [Abstract][Full Text] [Related]
3. Specific CCND1 G870A alleles associated with breast cancer susceptibility: a meta-analysis of 5,528 cases and 5,353 controls.
Cui J; Shen L; Wang Y
Asian Pac J Cancer Prev; 2012; 13(10):5023-5. PubMed ID: 23244103
[TBL] [Abstract][Full Text] [Related]
4. Association between cyclin D1 (CCND1) G870A polymorphism and gastric cancer risk: a meta-analysis.
Zhang Y; Zeng X; Lu H; Ji H; Zhao E; Li Y
Oncotarget; 2016 Oct; 7(40):66109-66118. PubMed ID: 27623072
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a case-control study and meta-analysis.
Liao D; Wu Y; Pu X; Chen H; Luo S; Li B; Ding C; Huang GL; He Z
PLoS One; 2014; 9(11):e113299. PubMed ID: 25409185
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis comprising 9,911 cases and 11,171 controls.
Sergentanis TN; Economopoulos KP
Mol Biol Rep; 2011 Nov; 38(8):4955-63. PubMed ID: 21161398
[TBL] [Abstract][Full Text] [Related]
7. Association between the Cyclin D1 G870A polymorphism and the susceptibility to and prognosis of upper aerodigestive tract squamous cell carcinomas: an updated meta-analysis.
Meng Y; Zhang C; Zhou X
Onco Targets Ther; 2016; 9():367-76. PubMed ID: 26855585
[TBL] [Abstract][Full Text] [Related]
8. Association between
Thakur N; Kumari S; Mehrotra R
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30361291
[No Abstract] [Full Text] [Related]
9. Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis.
Liu J; Liao Q; Zhang Y; Sun S; Zhong C; Liu X
Tumour Biol; 2012 Oct; 33(5):1467-76. PubMed ID: 22528945
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer.
Yuan L; Gu X; Shao J; Wang M; Wang M; Zhu Q; Zhang Z
DNA Cell Biol; 2010 Oct; 29(10):611-7. PubMed ID: 20575692
[TBL] [Abstract][Full Text] [Related]
11. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1.
Yu CP; Yu JC; Sun CA; Tzao C; Ho JY; Yen AM
Breast Cancer Res Treat; 2008 Jan; 107(1):95-102. PubMed ID: 18043898
[TBL] [Abstract][Full Text] [Related]
12. CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis.
Tang C; Wang Z; Yu J; Wu Y; Zhu Z; Chen N
Med Oncol; 2011 Dec; 28(4):1319-24. PubMed ID: 20443083
[TBL] [Abstract][Full Text] [Related]
13. The association between CCND1 G870A polymorphism and colorectal cancer risk: A meta-analysis.
Xie M; Zhao F; Zou X; Jin S; Xiong S
Medicine (Baltimore); 2017 Oct; 96(42):e8269. PubMed ID: 29049220
[TBL] [Abstract][Full Text] [Related]
14. Association between cyclin D1 G870A polymorphism and cervical cancer risk: a cumulative meta-analysis involving 2,864 patients and 3,898 controls.
Hu YY; Zheng R; Guo C; Niu YM
Diagn Pathol; 2014 Sep; 9():168. PubMed ID: 25204741
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study.
Zheng Y; Shen H; Sturgis EM; Wang LE; Eicher SA; Strom SS; Frazier ML; Spitz MR; Wei Q
Carcinogenesis; 2001 Aug; 22(8):1195-9. PubMed ID: 11470749
[TBL] [Abstract][Full Text] [Related]
16. Association between cyclin D1 G870A polymorphism and hepatocellular carcinoma risk: a meta-analysis.
Luo T; Chen J; Liu JJ; Li H; You XM; Wang HL; Zhu SL; Li LQ
Onco Targets Ther; 2016; 9():4483-9. PubMed ID: 27499641
[TBL] [Abstract][Full Text] [Related]
17. Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan.
Lin HH; Ke HL; Hsiao KH; Tsai CW; Wu WJ; Bau DT; Chang LL
Chin J Physiol; 2011 Jun; 54(3):196-202. PubMed ID: 21789902
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 (CCND1) G870A polymorphisms and cervical cancer susceptibility: a meta-analysis based on ten case-control studies.
Wu Y; Fu H; Zhang H; Huang H; Chen M; Zhang L; Yang H; Qin D
Tumour Biol; 2014 Jul; 35(7):6913-8. PubMed ID: 24737585
[TBL] [Abstract][Full Text] [Related]
19. Effect of the CCND1 A870G polymorphism on prostate cancer risk: a meta-analysis of 3,820 cases and 3,825 controls.
Zheng M; Wan L; He X; Qi X; Liu F; Zhang DH
World J Surg Oncol; 2015 Feb; 13():55. PubMed ID: 25888980
[TBL] [Abstract][Full Text] [Related]
20. CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis.
Lu C; Dong J; Ma H; Jin G; Hu Z; Peng Y; Guo X; Wang X; Shen H
Breast Cancer Res Treat; 2009 Aug; 116(3):571-5. PubMed ID: 18819000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
